TY - JOUR
T1 - Harnessing NK Cell Memory for Cancer Immunotherapy
AU - Fehniger, Todd A.
AU - Cooper, Megan A.
N1 - Funding Information:
Work in the Fehniger laboratory is supported by R01 AI102924, Leukemia SPORE P50 CA171963, the Siteman Cancer Center P30 CA91842, Gabrielle's Angel Foundation for Cancer Research, and the Leukemia and Lymphoma Society. Work in the Cooper laboratory is supported by the Rheumatology Research Foundation. Outstanding Questions
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Due to their ability to kill cancer cells and produce proinflammatory cytokines, natural killer (NK) cells have long been of clinical interest for their antitumor properties. The recent discovery of NK cell memory demonstrates that NK cell functions, and potentially antitumor responses, can be enhanced long term. Following nonspecific activation with the cytokines IL-12, IL-15, and IL-18 or in response to antigens or cytomegalovirus (CMV), human and mouse NK cells exhibit stable, enhanced functional responses with phenotypic and molecular changes. Here we review mechanisms driving the differentiation of NK cell memory-like properties, evidence for antitumor activity, and the challenges and opportunities in harnessing memory-like NK cells for cancer immunotherapy.
AB - Due to their ability to kill cancer cells and produce proinflammatory cytokines, natural killer (NK) cells have long been of clinical interest for their antitumor properties. The recent discovery of NK cell memory demonstrates that NK cell functions, and potentially antitumor responses, can be enhanced long term. Following nonspecific activation with the cytokines IL-12, IL-15, and IL-18 or in response to antigens or cytomegalovirus (CMV), human and mouse NK cells exhibit stable, enhanced functional responses with phenotypic and molecular changes. Here we review mechanisms driving the differentiation of NK cell memory-like properties, evidence for antitumor activity, and the challenges and opportunities in harnessing memory-like NK cells for cancer immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84999663822&partnerID=8YFLogxK
U2 - 10.1016/j.it.2016.09.005
DO - 10.1016/j.it.2016.09.005
M3 - Review article
C2 - 27773685
AN - SCOPUS:84999663822
SN - 1471-4906
VL - 37
SP - 877
EP - 888
JO - Trends in Immunology
JF - Trends in Immunology
IS - 12
ER -